SCHEMBL26554199

SCHEMBL26554199

C[C@H]1[C@@H](F)[C@H](n2cnc3c(N)ncnc32)O[C@@H]1C(=O)O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AHCY P23526 6/20 0.68
▸ HIF1A Q16665 1/20 0.68
▸ TMEM97 Q5BJF2 1/20 0.68
▸ SIGMAR1 Q99720 1/20 0.68
▸ ADORA2B P29275 5/20 0.58
▸ HSP90B1 P14625 4/20 0.58
▸ ADORA2A P29274 3/20 0.58
▸ ADORA3 P0DMS8 6/20 0.57
▸ TSHR P16473 4/20 0.57
▸ KMT2A Q03164 2/20 0.57
▸ HSP90AA1 P07900 2/20 0.57
▸ ADORA1 P30542 2/20 0.57
▸ LMNA P02545 1/20 0.57
▸ THRB P10828 1/20 0.57
▸ BLM P54132 1/20 0.57
▸ MAPK1 P28482 2/20 0.54
▸ CYP2C19 P33261 1/20 0.54
▸ TMIGD3 P0DMS9 1/20 0.54
▸ RXFP1 Q9HBX9 1/20 0.54
▸ MEN1 O00255 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12300947 1.00 AHCY (0.68) AHCYHIF1ATMEM97SIGMAR1ADORA2B
SCHEMBL26554188 0.88 AHCY (0.72) AHCYHIF1ATMEM97SIGMAR1ADORA2B
SCHEMBL19190163 0.87 AHCY (0.80) AHCYHIF1ATMEM97SIGMAR1ADORA2B
SCHEMBL18801554 0.87 AHCY (0.80) AHCYHIF1ATMEM97SIGMAR1ADORA2B
SCHEMBL13964644 0.87 AHCY (0.80) AHCYHIF1ATMEM97SIGMAR1ADORA2B
SCHEMBL19189442 0.87 AHCY (0.80) AHCYHIF1ATMEM97SIGMAR1ADORA2B
SCHEMBL13964672 0.87 ADORA2B (0.51) AHCYHIF1ATMEM97SIGMAR1ADORA2B
SCHEMBL13974288 0.87 AHCY (0.80) AHCYHIF1ATMEM97SIGMAR1ADORA2B
SCHEMBL19189542 0.87 AHCY (0.80) AHCYHIF1ATMEM97SIGMAR1ADORA2B
SCHEMBL12154738 0.87 AHCY (0.80) AHCYHIF1ATMEM97SIGMAR1ADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365970-A1 Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof ALIGOS THERAPEUTICS, INC. (US) 2023-11-16 — — US disclosed
US-20230332153-A1 Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof ALIGOS THERAPEUTICS, INC. (US) 2023-10-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365970-A1 Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof NSUN2, SNRPA, SNRPF AHCY 3101/4885HIF1A 1573/4885TMEM97 1392/4885
US-20230332153-A1 Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof NSUN2, SNRPA, SNRPF AHCY 3101/4885HIF1A 1573/4885TMEM97 1392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback